Yes Bunsnz,
- in their annual report they confirmed their estimated date to be Q4 for the approval of generic fonda, its market launch in the US and the commencement of PIII trial for HA-Irinotecan. And we should also hear more about the oral fonda opportunity.
- it was also confirmed in a recent article (posted by Sassy) where DrR confirmed they expect to get the go ahead this side of Christmas.
That said, I don't think we should take this as a certainty, but more like a likely milestone.
- Forums
- ASX - By Stock
- TSN
- jmp presentation
jmp presentation, page-22
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable